RSV prophylaxis use in high-risk infants in Western Australia, 2002-2013: a record linkage cohort study

BACKGROUND: The monoclonal antibody, palivizumab is licensed for use in high-risk infants to prevent severe illness caused by respiratory syncytial virus (RSV). The level of its use and compliance with current jurisdictional guidelines which were amended in 2010, is unknown. We determined the level...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMC Pediatr
Main Authors: Xu, Ruomei, Fathima, Parveen, Strunk, Tobias, de Klerk, Nicholas, Snelling, Thomas L., Richmond, Peter C., Keil, Anthony D., Moore, Hannah C.
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2020
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7584096/
https://ncbi.nlm.nih.gov/pubmed/33092566
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12887-020-02390-5
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados